North Immunology Joins Nasdaq Through Reverse Merger
North Immunology is now publicly traded via a reverse merger, taking a preclinical eczema candidate toward first-in-human trials with no disclosed trial date or target.
Topic
Topic
North Immunology is now publicly traded via a reverse merger, taking a preclinical eczema candidate toward first-in-human trials with no disclosed trial date or target.